AIToday
AI in HealthcareTop Companies' AI MovesAI Business & IndustryTop Companies AIPublished: Nov 18, 2026, 06:31 JST

Isomorphic Labs raises $5 billion in Series C

Send on LINE
Isomorphic Labs raises $5 billion in Series C

3 Key Points

  1. What happened

    Isomorphic Labs raised $5 billion in a Series C led by Greenoaks and Sequoia Capital, with Alphabet contributing and new investors including Andreesen Horowitz joining.

  2. Why it matters

    The company's two multibillion dollar rounds are the biggest venture capital infusions this year among the 26 firms tracked, suggesting investors are unfazed by the AI industry's stumble.

WHO IT HITSThe funding gives Isomorphic more runway to move from AI models to medicines, affecting its pharma partners like Novartis, Johnson & Johnson and Lilly, as well as rival AI drug discovery startups competing for investor attention.

Not sure about something? Ask the AI

Questions and answers are published on this page.

Summaries like this, every morning.

Context & Analysis

Isomorphic Labs' latest raise comes just months after a $2.1 billion Series B announced in May, meaning the Alphabet spinout has now pulled in two multibillion dollar rounds in a single year. That pace is notable because it coincides with a broader stumble in the AI industry, which the company's investors appear to have shrugged off. The financing is the largest among all rounds tracked since 2022, and the two rounds together represent the biggest venture capital infusions this year among the 26 firms BioPharma Dive tracks.

The money is meant to fund a shift in the company's business: from building AI models for drug discovery to actually bringing medicines into clinical trials. Isomorphic says it has seen positive preclinical results internally and with partners in oncology and immunology, which it describes as setting the stage for clinical entry. That step would mark a move beyond the industry's current state, where there is no approved medicine designed by AI.

Large drugmakers are moving in parallel. Bristol Myers Squibb, Merck & Co., Eli Lilly and Novo Nordisk have all announced significant investments or partnerships this year, and Isomorphic already counts Novartis, Johnson & Johnson and Lilly among its partners. Even so, proponents warn that AI is unlikely to be a quick fix for the risks and failures of pharmaceutical development, and the technology's ultimate impact remains unproven.

FAQ
Who led Isomorphic Labs' $5 billion funding round?
The Series C was led by Greenoaks and Sequoia Capital, with continued significant investment from Alphabet and new participation from Andreesen Horowitz.
What will Isomorphic Labs use the money for?
The funds will help Isomorphic move from developing AI models to bringing medicines to the clinic, and expand deeper into new biology.
Which pharma companies are partners of Isomorphic Labs?
Isomorphic counts Novartis, Johnson & Johnson and Lilly among its partners.
Top Companies AIRead Original Article
Send on LINE

Also reported by AI Weekly, SiliconANGLE AI, THE DECODER, TechCrunch AI

AI news that matters for your work, delivered every morning.

Pick your industry and the AI tools you use, and get news related to your work every day.

Free · 30 seconds with Google · unsubscribe anytimeWhat is AIToday? →

Ask AI

Ask AI anything about this article. The AI reads this article, earlier AIToday articles, and Wikipedia, and cites its sources. Q&As are published on this page for other readers too.

Questions and answers are published on this page.

Related Articles

Next articleSalesforce sets token budgets after staff spent thousands monthly